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Sonic spray ionization (SSI) was compared with atmospheric pressure chemical ionization
(APCI) as an interface of high-performance liquid chromatography (HPLC)-mass spectrometry
(MS) for sensitive analyses of a neuroleptic drug, haloperidol and its two metabolites, such as
reduced haloperidol and 4-(4-chlorophenyl)-4-hydroxypiperidine (CPHP), in biological sam-
ples. For both SSI and APCI interfaces, HPLC-MS-MS gave higher sensitivity than HPLC-MS.
The sensitivities by HPLC-SSI-MS-MS for haloperidol and reduced haloperidol were 100 and
30 times higher, respectively, than those by HPLC-APCI-MS-MS; no spectrum with recogniz-
able peaks was obtained for CPHP with the APCI interface. Therefore, detection limits and
regression equations were examined by the HPLC-SSI-MS-MS for human plasma and urine
samples spiked with the above drug and its metabolites. Haloperidol, reduced haloperidol,
and CPHP showed good linearity in the ranges of 5–800, 10–800, and 100–800 ng/mL,
respectively, for both human plasma and urine; their detection limits were 2.5, 5, and 75
ng/mL, respectively, using a new polymer HPLC column which enabled direct application of
biological samples. (J Am Soc Mass Spectrom 2001, 13, 204–208) © 2001 American Society for
Mass Spectrometry
Sonic spray ionization (SSI) was developed in 1994as a new technique to generate molecular ionsunder a very wide range of solvent systems and
liquid flow rates [1, 2], and has become commercially
available very recently as an interface of high-perfor-
mance liquid chromatography (HPLC) and mass spec-
trometry (MS). The mobile phase is electrically neutral;
however, in a small region, especially around the sur-
face layer of the solution, charge separation can occur.
In SSI, vaporization is done so that the surface layer of
the solution, in the region of charge separation, is
stripped by fast gas flow and electrically charged air-
borne droplets are created. The diameters of these
electrically charged droplets shrink by vaporization of
solvent molecules from the surface, and protonated
molecular ions are formed in the gas phase. These ions
enter the 3-dimensional quadrupole through the aper-
ture-1 and aperture-2 electrodes for mass analysis.
Organic compounds are ionized by nebulizing sample
solutions using a high-speed gas flow only, at room
temperature [1, 3].
In this study, HPLC-SSI-MS(-MS) has been com-
pared with HPLC-MS(-MS) with atmospheric pressure
chemical ionization (APCI), for analysis of haloperidol
and its two metabolites, reduced haloperidol and 4-(4-
chlorophenyl)-4-hydroxypiperidine (CPHP), in biologi-




Haloperidol, reduced haloperidol, and CPHP were
commercially obtained from Research Biochemical In-
ternational (Natick, MA). A haloperidol chlorinated
analog, 4-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-
(4-chlorophenyl)-1-butanone, used as internal standard
(I.S.) was also obtained from Research Biochemical
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International (Natick, MA). Reserpine was obtained
from Sigma (St. Louis, MO). Other common chemicals
used were of the highest purity commercially available.
Whole blood and urine were obtained from healthy
subjects. Whole blood was centrifuged at 1630 g for 15
min in the presence of EDTA-2Na (edetate disodium) to
obtain plasma.
MS-MS Conditions
An M-8000 ion trap mass spectrometer (LC/3DQMS,
Hitachi, Tokyo, Japan), equipped with SSI or APCI
interface was used for analyses. The mass calibration was
performed by flow injection of reserpine and haloperidol
as mass makers. All spectrometric detection was made in
the positive ionization mode. The MS-MS conditions for
SSI interface were optimized by sequential flow injection
of 1 ng/L (in the initial HPLC mobile phase described
below) of haloperidol, reduced haloperidol, the haloperi-
dol chlorinated analog, and CPHP at a flow rate of 20
L/min using a syringe pump; the conditions for APCI
interface were determined by sequential flow injection of
12.5 ng/L (in the initial HPLC mobile phase) of each
compound at a flow rate of 333 L/min.
Figure 1. Comparison of mass spectra of haloperidol (a), reduced haloperidol (b), haloperidol
chlorinated analog (c), and CPHP (d) obtained by SSI-HPLC-MS (A) with those by HPLC-APCI-MS
(B). A spectrum with a recognizable peak was not obtained for CPHP with APCI, even with the
injection of 62.5 g on-column.
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The MS-MS conditions optimized for haloperidol,
reduced haloperidol, haloperidol chlorinated analog,
and CPHP, for both SSI and APCI interfaces, were as
follows, respectively. Step of ion isolation (MS 1): Iso-
lation masses, m/z 375.39–376.64, 377.38–378.65,
391.36–392.67, and 211.51–212.51; low mass cutoff, m/z
368.49, 370.45, 384.17, and 207.26; isolation time, 10.00
ms for all compounds; isolation voltage, 0.050, 0.050,
0.050, and 0.015 V. Step of collisionally induced disso-
ciation (CID; MS 2): CID resonance, m/z 368.09–384.26;
390.00-410.00, 383.38–401.02, and 210.50–244.00; low
mass cutoff, m/z 130.00, 150.00, 120.00, and 105.17; CID
time, 50.00 ms for all compounds; CID voltage, 0.235,
0.185, 0.210, and 0.055 V.
SSI Interface Conditions
SSI conditions were as follows. The temperature of
cover plate, aperture-1, and aperture-2 were maintained
at 200, 150, and 120 °C, respectively, and the voltages of
drift, focus and SSI chamber were at 70, 30, and 0 V,
respectively. Nitrogen gas was supplied from N2 gas
generator AT-10NP-C (Air Tech, Yokohama, Japan)
with output pressure of 0.50 MPa and ion source inlet
pressure at 0.39 MPa. Helium gas was utilized as a
buffer gas with output pressure of 0.53 MPa and ion
source inlet pressure at 0.25 MPa.
APCI Interface Conditions
APCI conditions were as follows: The temperatures of
the nebulizer, desolvator, aperture-1, and aperture-2
were 230, 380, 150, and 120 °C, respectively, and the
voltages of drift, focus, needle, and detector were 70 V,
30 V, 3.5 kV, and 500 V, respectively. Helium was
utilized as a buffer gas with output pressure of 0.53
MPa and with ion source inlet pressure at 0.25 MPa.
HPLC Conditions
The HPLC column used was an Shodex MSpak
GF-310 4B, 50  4.6 mm i.d. (Showa Denko, Tokyo,
Japan). This column is made of a new polymer, which
enables direct injection of crude biological samples,
followed by size-exclusion chromatographic separa-
tion associated with slight action of partition and
adsorption. The mobile phase, consisting of distilled
water containing 0.09% formic acid and 20 mM
ammonium acetate (solvent A), was set at a flow rate
of 300 L/min for 5 min, and then gradient elution
was performed using 100% A to 20% A (80% solvent
B: Acetonitrile) over 20 min. The mobile phase was
discarded up to 5 min, and then introduced into the
mass spectrometer by a switching valve.




CID product ion spectra m/z
(% intensity)
CID product ion spectra m/z
(% intensity)
Haloperidol 165(100), 166(5) 165(100), 166(5), 194(6)
Reduced haloperidol 360(100), 361(12), 362(38), 363(6) 360(100), 361(9), 362(40), 363(7)
Haloperidol chlorinated analog 139(19), 181(100), 182(6), 183(22) 139(15), 141(9), 181(100), 182(7), 183(33)
CPHP 194(100), 196(31) Not available
aCID conditions are described in the text.
Table 2. Detection limits of HPLC-MS and HPLC-MS-MS with different interfaces (SSI and APCI) obtained by injection of the













Haloperidol 12.5 376 2.5 165
Reduced haloperidol 25 378 12.5 360
CPHP 1000 212 125 194
APCI
Haloperidol 1000 376 250 165
Reduced haloperidol 1000 378 375 360
CPHP Not detectable 212 — —
aHPLC-MS(-MS) conditions were identical to those for biological samples in this study. Detection limits were defined as the concentration at which
the analyte produced a chromatographic peak with a signal-to-noise ratio of 3. The injection onto the HPLC column was made at 18 concentrations
over range of 0.25 pg—62.5 g for all compounds.
bEach compound was monitored by the base peak of product ions generated by CID from each protonated molecular ion.
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Sample Preparation of Human Plasma and Urine
To 1 mL human plasma or urine in the presence of
haloperidol, its two metabolites and I.S. (300 ng), 3 mL
of the above initial HPLC mobile phase (solvent A) was
added. The mixture was frozen at 20 °C. After thaw-
ing, the mixture was centrifuged at 1630 g for 15 min. A
20 L aliquot of the supernatant fraction was directly
injected onto the HPLC column.
Results and Discussion
Figure 1 shows mass spectra of standard haloperidol
(Figure 1a), reduced haloperidol (Figure 1b), haloperi-
dol chlorinated analog (Figure 1c), and CPHP (Figure
1d) obtained by SSI-MS (A) and APCI-MS (B). Mass
spectra obtained with the SSI interface were similar to
those with the APCI interface except for CPHP, but
there seemed to be a trend of much smaller dehydration
fragment ions appearing in the mass spectra with the
SSI interface. In mass spectra of haloperidol for both SSI
and APCI, the protonated molecular ions at m/z 376 and
378, with an isotope ratio of3:1, due to the presence of
one chlorine atom, while the m/z 358 and 360 ions are
derived from a dehydration process. Other major ion at
m/z 165 for haloperidol is attributable to [F–C6H4–CO–
C3H6]
, which results from the charge-initiated cleav-
age of the alkyl carbon-nitrogen bond, with expulsion
of nitrogen–containing moiety as a neutral species. The
protonated molecular ions and fragment peaks due to
the above dehydration appeared for all compounds.
The ion at m/z 181 observed for haloperidol chlorinated
analog is also attributable to [Cl–C6H4–CO–C3H6]
.
Although we tried to record mass spectrum of CPHP
with the APCI interface, no recognizable peaks could be
obtained.
The typical product ions (% intensity) obtained by
CID from each protonated molecular ion for haloperi-
dol, reduced haloperidol, haloperidol chlorinated ana-
log, and CPHP are listed in Table 1. Each spectrum was
characteristic for each parent compound and thus pro-
vides the identification tool for each compound.
Table 2 shows comparison between detection limits
by HPLC-MS and HPLC-MS-MS with the different
interfaces (SSI and APCI), obtained by injecting various
amounts of standard compounds dissolved in the initial
mobile phase under the above mentioned HPLC condi-
tions. It was obvious that HPLC-MS-MS gave higher
sensitivity than HPLC-MS for both SSI and APCI inter-
faces. The sensitivities by HPLC-SSI-MS-MS for halo-
peridol and reduced haloperidol were 100 and 30 times
higher, respectively, than those by HPLC-APCI-MS-MS
under our conditions. Thus, we chose the SSI interface
for HPLC-MS-MS analyses of the three compounds.
Figure 2 shows chromatogram obtained by
HPLC-UV (at 280 nm) for monitoring proteins and
nucleic acids and mass chromatograms by HPLC-SSI-
MS-MS obtained from human plasma. As shown in the
HPLC-UV chromatogram, most of the proteins and
nucleic acids in plasma were eluted within 5 min.
Haloperidol, reduced haloperidol, CPHP, and I.S. were
well separated and could be determined simulta-
neously.
Detection limits and linearity of the methods for
haloperidol and its metabolites in plasma and urine
samples were carefully investigated over a concentra-
tion range of 1–800 ng/mL (14 points of concentra-
tions). The limits of detection (single-to-noise ratio  3)
for haloperidol, reduced haloperidol, and CPHP were
2.5, 5 and 75 ng/mL, respectively, for both plasma and
urine. Haloperidol, reduced haloperidol, and CPHP
showed good linearity in the range of 5–800, 10–800,
and 100–800 ng/mL, respectively, for both plasma and
Figure 2. Typical chromatogram of HPLC-UV and mass chro-
matograms by HPLC-SSI-MS-MS from a human plasma sample.
The amount of haloperidol, reduced haloperidol and CPHP
spiked to 1 ml plasma was 200 ng, and that of haloperidol
chlorinated analog (I.S.) was 300 ng. Each compound was moni-
tored by the base peak of product ions generated by CID from
each protonated molecular ion. Sample preparation before injec-
tion onto the HPLC column is described in the text. The peak
numbers: Peak 1, CPHP; Peak 2, reduced haloperidol; Peak 3,
haloperidol; Peak 4, I.S.
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urine. The correlation coefficients for these plots were
found to be 0.992, 0.987, and 0.934, respectively, for
plasma, and 0.992, 0.992, and 0.960, respectively, for
urine.
SSI is a soft ionization method which does not
require heat or high voltages to form ions; therefore, it
is well suited for ionization of substances, which is
sensitive to heat decomposition [1, 2]. SSI is quite
different in principle from APCI and electrospray ion-
ization (ESI); the latter is also widely used as an
interface of HPLC-MS(-MS) at the present time. We thus
tried analysis of CPHP by using a Finnigan MAT LCQ
ion trap mass spectrometer (San Jose, CA) with the ESI
interface, but no spectrum with recognizable peaks of
CPHP could be obtained by mean of sequential flow
injection as with the APCI interface in the present study
(unpublished observation). It seems correct that SSI
shows broader spectrum for organic compounds to be
ionized.
Haloperidol is one of the most important neuroleptic
drugs widely used. The drug and/or its metabolites
were analyzed by gas chromatography (GC)-MS(-MS)
[4, 5], HPLC-APCI-MS [6], HPLC-ESI-MS(-MS) [6–10],
and HPLC-thermospray-MS-MS [11]. A hydrophobic
drug is usually metabolized in the body to hydrophilic
metabolite(s), and excreted into urine. It is therefore
important to analyze a hydrophobic drug and its hy-
drophilic metabolite(s) simultaneously by a single in-
terface of HPLC-MS(-MS). However, CPHP (a hydro-
philic metabolite) could not be analyzed with the
popular interfaces such as APCI and ESI. In this respect,
our HPLC-SSI-MS-MS method seems recommendable.
Conclusions
To our knowledge, this is the first trial to compare the
SSI with the APCI as an interface of HPLC-MS(-MS) for
analysis of a drug and its metabolite(s). The sensitivities
by HPLC-SSI-MS-MS for haloperidol and reduced hal-
operidol were 100 and 30 times higher, respectively,
than those by HPLC-APCI-MS-MS under our condi-
tions; CPHP could be detected by HPLC-SSI-MS(-MS),
but not by HPLC-APCI-MS(-MS). Based on the compar-
ison, we have established a detailed procedure for
simultaneous analysis of haloperidol and its two me-
tabolites in human plasma and urine by the HPLC-SSI-
MS-MS coupled with a special HPLC column.
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